Houston Texans fans can now make purchases with cryptocurrency, thanks to Houston-based BitWallet. Image via houstontexans.com

The Houston Texans are making a major pass into the crypto space.

A new partnership has made it the first team in the NFL to allow the sale of its suites through digital currency.

In an agreement announced this week, the Houston Texans have partnered with Houston-based cryptocurrency company, BitWallet, to become the official digital currency wallet of the organization. The partnership goes into effect immediately.

Through this partnership, fans now can use cryptocurrency to purchase single game suites, using BitWallet as the means to convert the cryptocurrency into U.S. dollars.

"We are proud to partner with BitWallet to offer an exciting option for our fans who are looking to enjoy Texans gameday in one of our suites," says Houston Texans President Greg Grissom. "BitWallet is a perfect collaborator as we continue our efforts to move our organization forward in new and innovative ways."

BitWallet was founded by CEO John Perrone in 2017 and has raised $2.1 million in seed over one round, according to CrunchBase.

"Digital currency has become a primary means of payment and by partnering with BitWallet, the Texans are leading the way in the NFL," Perrone says. "I am honored that BitWallet is the first to offer Texans fans this service."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”